Table 1.

Histology, mutation, and response to chemotherapy in TNBC PDX derived from residual tumors after neoadjuvant chemotherapy

PDX response: % TGI and RECIST criteria
PDXNeoadjuvant treatment of TNBC patientsTumor histologyTP53 and BRCA1/2 mutationsACDocetaxelCisplatinCapecitabine
HBCx-12ADocetaxelIDCNone44 (PD)28 (PD)0 (PD)96 (SD)
HBCx-39EC + docetaxelIDCTP5336 (PD)0 (PD16 (PD)98 (R)
HBCx-48FEC docetaxelIDCTP5330 (PD)0 (PD)40 (PD)37 (PD)
HBCx-63FEC docetaxelIDCTP5374 (PD)30 (PD)86 (PD)96 (SD)
HBCx-66FEC docetaxelMBCBRCA194 (R)0 (PD)98 (R)41.4 (PD)
HBCx-69FEC docetaxelMBCTP5331 (PD)50 (PD)64 (PD)55 (PD)
HBCx-92EC docetaxelIDCBRCA274 (PD)30 (PD)90 (PD)93 (SD)
HBCx-90PaclitaxelMBCTP5381 (PD)35 (PD)89 (PD)0 (PD)
HBCx-95FEC docetaxelIDCNone0 (PD)32 (PD)50 (PD)100 (R)
HBCx-106FEC docetaxelIDCTP5375 (PD)43 (PD)69 (PD)90 (SD)
  • Abbreviations: AC, adriamycin + cyclophosphamide; CR, complete response; FEC, 5-FU, epirubicin, cyclophosphamide; IDC, invasive ductal carcinoma; MBC, metaplastic breast cancer; PD, progressive disease; R, regression; SD, stable disease; TGI, tumor growth inhibition.